NBDF showcases a wide array of findings from the latest in bleeding disorders research at our annual Bleeding Disorders Conference.
Efficacy, safety, and pharmacokinetics of a high-purity plasma-derived factor X (pdFX) concentrate in the prophylaxis of bleeding episodes in children <12 years with moderate to severe congenital factor X deficiency (FXD)
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia A and B with and Without Inhibitors: Interim Results from a Phase 2 Extension Study
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Assessing the Availability and Use of Resources to Support Youth with Hemophilia, their Families and Care Teams during Transition to Adult Health Care
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Collaboration/Team Models
Survey Finds Interest in Bleeding Disorder Social Work Specialty Credentialing
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Psychosocial Issues
Physician practice patterns in the US show significant variation in how PK parameters are currently used to personalize care for US hemophilia A patients
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Attitudes and Perspectives on Ankle Function in People with Hemophilia: A Qualitative Study
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Orthopedic and Physical Therapy
Impact of targeted education on obesity in children with hemophilia-a single HTC quality project
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
BAY 94-9027, a Site-Specifically PEGylated Recombinant Factor VIII: Preliminary Results From a Global Comparative Laboratory Field Study
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
The WFH Launches World Bleeding Disorders Registry to Expand Knowledge Base Worldwide
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Journey to Best Outcomes in Hemophilia Transition: Passage to Independence
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Collaboration/Team Models
Lessons Learned From the Assessment and Prevalence of Anxiety and Depression in US Adults With Hemophilia in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study: Importance of Routine Screening and Comprehensive Approaches to Management
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Optimal dosing strategies evaluated using a model of the terminal half-life curves for 11 rFVIII products
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Peer Support/Outreach/Integration Models
Assessment of numeracy, genetic knowledge and perceptions of genetic testing in carriers of Hemophilia A and B
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Women's Research
BAY 81-8973: Safety Observations in Clinical Trials in Adults, Adolescents, and Children With Severe Hemophilia A
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Patient Preferences for FVIII and BAX 855: Results from the BAX 855 Pivotal Trial
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Reported Increased or Maintained Physical Activity in the A-LONG and Kids A-LONG Studies
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Hemophilia B Patients Who Switch From rFIX to Extended Half-Life rFIX-Fc: A Retrospective Analysis of Cost using US Specialty Pharmacy Dispensing Data
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Associations Between Annual Bleeding Episodes and Financial Burden of Illness Among Persons with Hemophilia A and B in the United States
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Increased physical activity levels and improvement in treatment outcomes in patients who switch from on-demand to prophylaxis with BAX 855
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Pegylated full-length recombinant factor VIII (BAX 855) for prophylaxis in previously treated adolescent and adult patients with severe hemophilia A
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials